HRP20160183T1 - Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava - Google Patents
Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava Download PDFInfo
- Publication number
- HRP20160183T1 HRP20160183T1 HRP20160183T HRP20160183T HRP20160183T1 HR P20160183 T1 HRP20160183 T1 HR P20160183T1 HR P20160183 T HRP20160183 T HR P20160183T HR P20160183 T HRP20160183 T HR P20160183T HR P20160183 T1 HRP20160183 T1 HR P20160183T1
- Authority
- HR
- Croatia
- Prior art keywords
- independently
- ring
- bone
- compound according
- image
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 4
- XDTYUYVIGLIFCW-UHFFFAOYSA-N 4-phenylbenzenesulfonic acid Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C1=CC=CC=C1 XDTYUYVIGLIFCW-UHFFFAOYSA-N 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000001424 substituent group Chemical group 0.000 claims 13
- 206010061218 Inflammation Diseases 0.000 claims 12
- 230000004054 inflammatory process Effects 0.000 claims 12
- 206010065687 Bone loss Diseases 0.000 claims 10
- 230000004913 activation Effects 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000000987 immune system Anatomy 0.000 claims 6
- 210000002997 osteoclast Anatomy 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 5
- 208000006386 Bone Resorption Diseases 0.000 claims 4
- 208000020084 Bone disease Diseases 0.000 claims 4
- 102000000589 Interleukin-1 Human genes 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 208000016738 bone Paget disease Diseases 0.000 claims 4
- 230000024279 bone resorption Effects 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 210000001503 joint Anatomy 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- -1 C5-6-heteroaryl Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010023203 Joint destruction Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000027067 Paget disease of bone Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 230000008105 immune reaction Effects 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000002865 osteopetrosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000002476 tumorcidal effect Effects 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
Claims (20)
1. Spoj, naznačen time, da je odabran od spojeva sljedeće formule, i njegove farmaceutski prihvatljive soli, njegovi hidrati i solvati:
[image]
gdje:
Ar1-Ar2-je neovisno skupina sljedeće formule:
[image]
q je neovisno 0, 1, 2, 3 ili 4;
r je neovisno 0, 1, 2, 3, 4 ili 5;
Svaki RP je neovisno supstitent u prstenu;
-RN je neovisno –H ili –C1-6-alkil;
-Ar3- je neovisno 1,3-fenilen ili 1,4-fenilen, i neovisno je nesupstituiran ili je supstituiran s jednim ili više
supstituenata, -RAR3, gdje svaki -RAR3 je neovisno supstituent u prstenu:
-Z je neovisno -OH ili -0-W;
-J- je neovisno -Ralk-;
-Ralk-je neovisno zasićeni alifatski C1-5-alkilen, i neovisno je nesupstituiran ili je supstituiran s jednim ili više
upstituenata, -RAA, gdje svaki -RAA je neovisno:
-F, -Cl, -Br, -I, -OH ili OMe;
-W je neovisno sljedeće:
[image]
pri čemu:
svaki n je neovisno 1, 2, 3 ili 4; i
svaki od RE1, RE2, RE3, RE4, RE5, RE6, RE7, RE8, RNE1, RNE2, RN3, RNE4 i RNE5 je neovisno -H, C1-3-alkil, fenil, ili
CH2-fenil;
gdje je svaki fenil opcijski supstituiran s jednom ili više skupina odabranih od sljedećih:
-F, -Cl, -Br, -I, -RA3, -CF3, -OH, -ORA3, -OCF3, -NH2, -NHRA3, -NRA32, -C(=O)NH2, -C(=O)NHRA3 i
C(=O)NRA32, dok je svaki RA3 neovisno C1-4-alkil;
Pri čemu je supstitent u prstenu neovisbo sljedeći:
[image]
i pritom dodatno, dva susjedna supstituenta u prstenu, mogu zajedno tvoriti skupinu -O-L1-O-, gdje L1 je
neovisno zasićeni alifatski C1-3-alkilen; i pri čemu:
u svakoj skupini -NRN1RN2, Rn1 i RN2 kada se uzmu zajedno s dušikovim atomom na kojega su priključeni,
tvore 5-člani, 6-člani ili 7-člani nearomatski prsten koji ima točno jedan heteroatom u prstenu ili točno dva
heteroatoma u prstenu, gdje jedan od navedena točno dva heteroatoma u prstenuje N, a preostali od navedena
točno dva heteroatoma u prstenu, neovisno je N ili O;
svaki od -RD1 je neovisno -RD2, -RD3, -RD4, -RD5, -RD6, -L2-RD3, -L2-RD4, -L2-RD5 ili -L2RD6, dok:
svaki od –RD2 je neovisno zasićeni alifatski C1-6-alkil;
svaki od -RD3 je neovisno fenil;
svaki od -RD4 je neovisno C5-6-heteroaril;
svaki od -RD5 je neovisno C3-6-cikloalkil ili C3-6-cikloalkenil;
svaki od -RD6 je neovisno nearomatski C3-6-heterociklil; i
svaki od -L2 je neovisno zasićeni alifatski C1-3-alkilen;
i pri čemu:
svaki C1-6-alkil, fenil, C5-6-heteroaril, C3-6-cikloalkil, C3-6-cikloalkenil, C3-6-heterociklil i C1-3-alkilen je opcijski
supstituiran s jednim ili više supstituenata odabranih od sljedećih:
-F, -Cl, -Br, -I, -RF1, -CF3, -OH, -ORf1, -OCF3, -SH, -SRF1, -CN, -NO2, -NH2, -NHRf1, -NRfi2, -NRN3RN4,
C(=O)OH, -C(=O)ORfi, -C(=O)NH2, -C(=O)NHRf1, -C(=O)NRf12, -C(=O)NRN3RN4, -L3-OH, -L3-ORF1, -L3-
NH2, -L3-NHRF1, -L3-NRF12 i -L3-NRN3RN4;
gdje:
svaki -Rfi je neovisno zasićeni alifatski C1-4-alkil; svaki -L - je neovisno zasićeni alifatski C2-5-alkilen; i
u svakoj skupini -NRN3RN4, RN3 i RN4 kada se uzmu zajedno s dušikovim atomom na kojega su priključeni,
tvore 5-člani, 6-člani ili 7-člani nearomatski prsten koji ima točno jedan heteroatom u prstenu ili točno dva
heteroatoma u prstenu, gdje jedan od navedena točno dva heteroatoma u prstenuje N, a preostali od navedena
točno dva heteroatoma u prstenu, neovisno je N ili O.
2. Spoj prema zahtjevu 1, naznačen time, da -Z je neovisno -OH.
3. Spoj prema zahtjevu 1 ili 2, naznačen time, da Ar1-Ar2-je neovisno skupina sljedeće formule:
[image]
gdje RP je neovisno supstituent u prstenu; ili gdje Ar1-Ar2-je neovisno skupina sljedeće formule:
[image]
gdje Rp je neovisno supstituent u prstenu; ili gdje Ar1-Ar2-je neovisno skupina sljedeće formule:
[image]
gdje Rp je neovisno supstituent u prstenu; ili gdje Ar1-Ar2-je neovisno skupina sljedeće formule:
[image]
gdje Rp je neovisno supstituent u prstenu; ili gdje Ar1-Ar2- je neovisno skupina sljedeće formule:
[image]
4. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da -RN je neovisno -H.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time, da -Ralk- je neovisno –CH2 ili -(CH2)2.
6. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time, da -Ralk- je neovisno -CH2-.
7. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da svaki -RD1, ako je prisutan, neovisno je –RD8, dok svaki -RD8 je neovisno -RD2, -RD3 ili -CH2-RD3.
8. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da svaki -RD1, ako je prisutan, neovisno je -RD9, dok svaki -RD9 je neovisno zasićeni alifatski C1-3-alkil.
9. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da svaki supstituent u prstenu, ako je prisutan, neovisno je sljedeći: -F, -Cl, -Br, -I, -RD8, -CF3, -OH, -ORD8, -OCF3, -SRD8, -CN, -NO2, -NH2, -NHRD8, -NRD82, -C(=O)OH ili -C(=O)ORD8, dok svaki -RD8 je neovisno -RD2, -RD3 ili -CH2-RD3.
10. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da svaki supstituent u prstenu, ako je prisutan, neovisno je sljedeći: -F, -Cl, -Br, -I, -Me, -CF3, -OH, -OMe, -OCF3, -NO2 -NH2, -NHMe ili -NMe2.
11. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da svaki supstituent u prstenu, ako je prisutan, neovisno je sljedeći: -F, -Cl ili -Br.
12. Spoj prema bilo kojem od zahtjeva 1 do 11, naznačen time, da -Ar3- je neovisno nesupstituiran.
13. Spoj prema zahtjevu 1, naznačen time, daje odabran od spojeva sljedećih formula i njegove farmaceutski prikladne soli, njegovi hidrati i solvati:
[image]
[image]
[image]
[image]
[image]
14. Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 13 i farmaceutski prikladan nosač ili razrjeđivač.
15. Farmaceutski sastav za oralnu primjenu, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 13 i farmaceutski prikladan nosač ili razrjeđivač.
16. Spoj prema bilo kojem od zahtjeva 1 do 13, naznačen time, da se upotrebljava u postupku obrade ljudskog ili životinjskog tijela pomoću liječenja.
17. Spoj prema bilo kojem od zahtjeva 1 do 13, naznačen time, da se upotrebljava u postupku liječenja i/ili prevencije sljedećih stanja:
upalni poremećaj ili autoimuni poremećaj;
poremećaj povezan s upalom i/ili s aktiviranjem imunološkog sustava;
poremećaj posredovan prekomjernim i/ili neprikladnim i/ili produljenim aktiviranjem
imunološkog sustava;
upala;
poremećaj povezan s upalom ili s aktiviranjem imunološkog sustava;
reumatoidni artritis;
psorijaza;
psorijatički artritis;
ankilozni spondilitis;
upalna bolest crijeva;
imunološka reakcija koja vodi do odbacivanja organa ili presadaka nakon transplantacije; tumor koji prekomjerno
izražava TNFα, IL-1 ili RANKL, ili kod kojega inhibicija za TNFα, IL-1 ili za RANKL, olakšava ili poboljšava
djelovanje citotoksičnih tumoricidnih sredstava;
poremećaj posredovan putem osteoklasta;
poremećaj karakteriziran prekomjernom resorpcijom kostiju;
gubitak kostiju;
gubitak kostiju povezan s upalom;
gubitak kostiju koji nije povezan s upalom;
gubitak kostiju povezan s prekomjernim aktiviranjem osteoklasta;
razaranje zglobova;
razaranje zglobova povezano s upalom;
razaranje zglobova povezano s prekomjernim aktiviranjem osteoklasta;
gubitak kostiju povezan s reumatoidnim artritisom, osteoporozom, bolešću kostiju koja je
povezana s rakom ili Pagetovom bolešću kostiju;
reumatoidni artritis, osteoporoza, bolest kostiju povezana s rakom ili Pagetova bolest kostiju;
neoplazija kostiju;
hiperkalcemija uzrokovana stanjima koja su povezana s povećanjem resorpcije kostiju; aseptičko olabavljenje
prostetičkih implantata; osteopetroza, osteoartritis ili ektopične tvorbe kostiju.
18. Spoj za uporabu prema zahtjevu 17, naznačen time, da navedeno liječenje i/ili prevencija obuhvaća oralnu primjenu spoja.
19. Uporaba spoja prema bilo kojem od zahtjeva 1 do 13, naznačena time, da je za proizvodnju lijeka za liječenje i/ili prevenciju sljedećih stanja:
upalni poremećaj ili autoimuni poremećaj;
poremećaj povezan s upalom i/ili s aktiviranjem imunološkog sustava;
poremećaj posredovan prekomjernim i/ili neprikladnim i/ili produljenim aktiviranjem
imunološkog sustava;
upala;
poremećaj povezan s upalom ili s aktiviranjem imunološkog sustava;
reumatoidni artritis;
psorijaza;
psorijatički artritis; ankilozni spondilitis; upalna bolest crijeva;
imunološka reakcija koja vodi do odbacivanja organa ili presadaka nakon transplantacije;
tumor koji prekomjerno izražava TNFa, IL-1 ili RANKL, ili kod kojega inhibicija za TNFa, IL-l ili za RANKL,
olakšava ili poboljšava djelovanje citotoksičnih tumoricidnih sredstava;
poremećaj posredovan putem osteoklasta;
poremećaj karakteriziran prekomjernom resorpcijom kostiju;
gubitak kostiju;
gubitak kostiju povezan s upalom;
gubitak kostiju koji nije povezan s upalom;
gubitak kostiju povezan s prekomjernim aktiviranjem osteoklasta;
razaranje zglobova;
razaranje zglobova povezano s upalom;
razaranje zglobova povezano s prekomjernim aktiviranjem osteoklasta;
gubitak kostiju povezan s reumatoidnim artritisom, osteoporozom, bolešću kostiju koja je
povezana s rakom ili Pagetovom bolešću kostiju;
reumatoidni artritis, osteoporoza, bolest kostiju povezana s rakom ili Pagetova bolest kostiju;
neoplazija kostiju;
hiperkalcemija uzrokovana stanjima koja su povezana s povećanjem resorpcije kostiju; aseptičko olabavljenje prostetičkih implantata; osteopetroza, osteoartritis ili ektopične tvorbe kostiju.
20. Uporaba prema zahtjevu 19, naznačena time, da navedeni lijek je lijek za oralnu primjenu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0705400.0A GB0705400D0 (en) | 2007-03-21 | 2007-03-21 | Therapeutic compounds andm their use |
| EP08718826.4A EP2137141B1 (en) | 2007-03-21 | 2008-03-20 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents |
| PCT/GB2008/000989 WO2008114022A1 (en) | 2007-03-21 | 2008-03-20 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160183T1 true HRP20160183T1 (hr) | 2016-03-25 |
Family
ID=38024559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160183T HRP20160183T1 (hr) | 2007-03-21 | 2016-02-22 | Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8524778B2 (hr) |
| EP (1) | EP2137141B1 (hr) |
| JP (1) | JP5450105B2 (hr) |
| CA (1) | CA2681320C (hr) |
| DK (1) | DK2137141T3 (hr) |
| ES (1) | ES2561163T3 (hr) |
| GB (1) | GB0705400D0 (hr) |
| HR (1) | HRP20160183T1 (hr) |
| HU (1) | HUE028656T2 (hr) |
| SI (1) | SI2137141T1 (hr) |
| WO (1) | WO2008114022A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB0817208D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| US9233946B2 (en) | 2010-09-17 | 2016-01-12 | Kancera Ab | Sulfonamide compounds |
| EP2717869B1 (en) * | 2011-06-13 | 2019-02-27 | Ergon Pharmaceuticals LLC | Methods of treatment using a bcat1 inhibitor |
| US10941109B2 (en) | 2011-06-13 | 2021-03-09 | Ergon Pharmaceuticals Llc | Compositions and methods of treatment using a BCAT1 inhibitor |
| US9708276B2 (en) | 2011-10-12 | 2017-07-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| WO2013093095A1 (en) * | 2011-12-22 | 2013-06-27 | Kancera Ab | Bisarylsulfonamides useful in the treatment of inflammation and cancer |
| CN108409613A (zh) * | 2012-12-10 | 2018-08-17 | 弗·哈夫曼-拉罗切有限公司 | 作为RORc调节剂的苄基磺酰胺衍生物 |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| JP6564380B2 (ja) | 2013-09-20 | 2019-08-21 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 前立腺癌を治療するための化合物 |
| EP3262028B1 (en) | 2014-12-17 | 2021-10-27 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
| US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| KR102457657B1 (ko) | 2017-02-07 | 2022-10-21 | 리프스톤 비.브이. | 무균성 해리로 인한 임플란트 관련 임플란트 교정 위험을 진단하기 위한 바이오마커 |
| US11555012B2 (en) * | 2018-11-09 | 2023-01-17 | Nimbus Artemis, Inc. | ACLY inhibitors and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB597810A (en) | 1943-04-12 | 1948-02-04 | Gen Printing Ink Corp | Improvements in or relating to derivatives of diphenyl |
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| GB2001307A (en) * | 1977-07-01 | 1979-01-31 | American Cyanamid Co | Sulphonamide blood complement inhibitors |
| US4119784A (en) * | 1977-07-01 | 1978-10-10 | American Cyanamid Company | Anionic substituted sulfonamido biphenyls |
| DE3000519A1 (de) | 1979-02-01 | 1980-08-14 | Byk Gulden Lomberg Chem Fab | Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
| DE3535167A1 (de) * | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| KR19990067184A (ko) | 1995-10-30 | 1999-08-16 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | 프로테아제 억제제 |
| US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| AU2421797A (en) | 1996-03-15 | 1997-10-01 | Du Pont Pharmaceuticals Company | Spirocycle integrin inhibitors |
| EP0939629A4 (en) | 1996-07-22 | 2002-07-17 | Monsanto Co | THIOL-SULFONAMIDES AS METALLOPROTEINAS INHIBITORS |
| IL129147A0 (en) | 1996-10-16 | 2000-02-17 | American Cyanamid Co | The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| ATE342262T1 (de) | 1996-11-27 | 2006-11-15 | Bristol Myers Squibb Pharma Co | Neue integrin rezeptor antagonisten |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| CA2289602A1 (en) | 1997-05-08 | 1998-11-12 | William Edward Bondinell | Protease inhibitors |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| DK0877019T3 (da) * | 1997-05-09 | 2002-04-08 | Hoechst Ag | Substituerede diaminocarboxylsyrer |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| HUP0100520A3 (en) | 1998-01-23 | 2002-11-28 | Genentech Inc | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| HUP0101176A3 (en) | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
| JPH11246527A (ja) | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Ｍｍｐ−８阻害剤 |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| CN1418210A (zh) * | 2000-03-21 | 2003-05-14 | 宝洁公司 | 含有碳环侧链的n－取代金属蛋白酶抑制剂 |
| AU2001264595A1 (en) | 2000-05-19 | 2001-12-03 | Guilford Pharmaceuticals Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU2002228316A1 (en) | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| WO2002074298A1 (fr) | 2001-03-21 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Inhibiteurs de production d'il-6 |
| JP2004535390A (ja) * | 2001-05-07 | 2004-11-25 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| MXPA04001253A (es) | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
| GB0126157D0 (en) * | 2001-10-31 | 2002-01-02 | Univ Aberdeen | Therapeutic compounds |
| TW200305396A (en) | 2002-03-27 | 2003-11-01 | Shionogi & Co | Cartilage extracellular matrix degradation |
| KR101088922B1 (ko) | 2002-09-04 | 2011-12-01 | 파마코페이아, 엘엘씨. | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
| DE10251170A1 (de) * | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| ES2298753T3 (es) | 2003-05-07 | 2008-05-16 | The University Court Of The University Of Aberdeen | Cetonas y cetonas reducidas como agentes terapeuticos para el tratamiento de enfermedades oseas. |
| JPWO2004106290A1 (ja) | 2003-05-14 | 2006-07-20 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| GB0324792D0 (en) * | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| WO2005060963A1 (en) | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| GB0405193D0 (en) | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| WO2005105712A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Sulfonamide derivatives |
| GB0412553D0 (en) * | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| WO2005123089A2 (en) * | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| EA200702498A1 (ru) | 2005-06-16 | 2008-06-30 | Пфайзер Инк. | N-(пиридин-2-ил)сульфонамидные производные |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| TW200720261A (en) * | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
| BRPI0620756B1 (pt) * | 2005-12-29 | 2021-06-01 | Tersera Therapeutics Llc | Derivados de aminoácido multicíclicos, formulação farmacêutica compreendendo os mesmos e seus usos para inibir a atividade de triptofano hidroxilase 1 (tph1) |
| US7560597B2 (en) * | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
-
2007
- 2007-03-21 GB GBGB0705400.0A patent/GB0705400D0/en not_active Ceased
-
2008
- 2008-03-20 CA CA2681320A patent/CA2681320C/en active Active
- 2008-03-20 ES ES08718826.4T patent/ES2561163T3/es active Active
- 2008-03-20 DK DK08718826.4T patent/DK2137141T3/en active
- 2008-03-20 EP EP08718826.4A patent/EP2137141B1/en active Active
- 2008-03-20 WO PCT/GB2008/000989 patent/WO2008114022A1/en active Application Filing
- 2008-03-20 HU HUE08718826A patent/HUE028656T2/en unknown
- 2008-03-20 JP JP2009554083A patent/JP5450105B2/ja active Active
- 2008-03-20 US US12/531,732 patent/US8524778B2/en active Active
- 2008-03-20 SI SI200831582T patent/SI2137141T1/sl unknown
-
2016
- 2016-02-22 HR HRP20160183T patent/HRP20160183T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB0705400D0 (en) | 2007-05-02 |
| CA2681320C (en) | 2015-05-19 |
| SI2137141T1 (sl) | 2016-03-31 |
| US8524778B2 (en) | 2013-09-03 |
| EP2137141B1 (en) | 2015-12-02 |
| ES2561163T3 (es) | 2016-02-24 |
| WO2008114022A1 (en) | 2008-09-25 |
| EP2137141A1 (en) | 2009-12-30 |
| HUE028656T2 (en) | 2016-12-28 |
| JP2010522152A (ja) | 2010-07-01 |
| US20100286266A1 (en) | 2010-11-11 |
| DK2137141T3 (en) | 2016-02-29 |
| JP5450105B2 (ja) | 2014-03-26 |
| CA2681320A1 (en) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160183T1 (hr) | Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava | |
| JP7380507B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| JP2010522152A5 (hr) | ||
| JP6721499B2 (ja) | 骨の成長を促進するためのアルキルアミンハルミン誘導体 | |
| CA3108714A1 (en) | Pyrrolo - dipyridine compounds | |
| JP2007501281A5 (hr) | ||
| RU2005122901A (ru) | Производные пиридино [2,3-] пиримидина в качестве селективных ингибиторов kdr и fgfr | |
| CN101365461B (zh) | 舒林酸衍生物、其用途和其制备 | |
| EA002822B1 (ru) | Антагонисты рецептора интегрина | |
| AR008677A1 (es) | Acidos orto-sulfonamido heteroaril hidroxamicos como inhibidores de la metalproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos y composicion farmaceutica que los contiene | |
| ATE286501T1 (de) | Pyrimidinderivate | |
| EP1586564A1 (en) | 8-azaprostaglandin derivatives and medicinal uses thereof | |
| EE200200220A (et) | Uudsed tsüklopropaanid kui CGRP antagonistid, neid ühendeid sisaldavad ravimid ja meetodid nende valmistamiseks | |
| JP2013129632A (ja) | Ｅｎｐｐ２阻害化合物 | |
| RU2007115522A (ru) | Пери-замещенные бициклические карбоновые кислоты для лечения окклюзионного заболевания артерий | |
| US9173946B2 (en) | Bifunctional hydroxy-bisphosphonic acid derivatives | |
| AR032327A1 (es) | Un compuesto derivado del acido propanoico, su uso, una composicion farmaceutica que lo comprende, y un producto que contiene el compuesto derivado del acido propanoico y un agente antitumoral adicional | |
| WO2020037001A1 (en) | FLUORO β-CARBOLINE COMPOUNDS | |
| KR101191733B1 (ko) | 파골세포 분화 억제 효과를 갖는 신규한 화합물 및 이를 포함하는 약학적 조성물 | |
| EP3867282B1 (en) | Conjugates of hyaluronic acid and aminobisphosphonates and the therapeutic use thereof | |
| KR20170091610A (ko) | 신규 peg 유도체 | |
| TWI492920B (zh) | 水楊酸苯胺衍生小分子之醫藥組合物及其製備與醫藥用途 | |
| RU2019111768A (ru) | Противораковые агенты и их получение | |
| AU759249B2 (en) | Barbituric acid derivative and preventive and therapeutic agent for bone and cartilage containing the same | |
| ES2232425T3 (es) | Tiazol-2-iliden-aminas policiclicas, procedimiento para su preparacion y su utilizacion como medicamentos. |